Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

AlzeCure Pharma AB describes new compounds for AD

March 19, 2021

Preliminary phase I/II results for SGT-001 in DMD support its further investigation

March 19, 2021

Lipopolysaccharides induce neural repair sweet spot

March 18, 2021

Chinese phase I study begins with LPM-3480392

March 18, 2021

Annovis reports phase IIa interim data on ANVS-401 in Parkinson's patients

March 17, 2021

Biohaven Therapeutics identifies compounds targeting TDP-43

March 17, 2021

Lipid dysregulation gives information on Parkinson's

March 17, 2021

DAPK1 as a potential new target in Alzheimer's disease

March 16, 2021

Galapagos describes new ENPP2 inhibitors

March 16, 2021

SiteOne initiates phase I study of ST-2427 in healthy volunteers

March 15, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 20, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
WHO declares Ebola outbreak a public health emergency of international concern
BioWorld
The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...
Nxera Pharma prepares and tests new GPR17 antagonists
BioWorld Science
Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...